Lipoproteína(a)
Grupo Argentino Estudio Lipoproteína (a)
.png)
¿A quien medir?
En la actualidad hay consenso en que la Lp(a) debería medirse en todos los adultos al menos una vez en la vida. La Sociedad Europea de Ateroesclerosis (EAS)(1), la Sociedad Canadiense Cardiovascular (CCS)(2) y la Sociedad Europea de Cardiología (ESC)(3) coinciden en dicha recomendación.
a%20quien%20medir%20figura1.png)
Guías Clínicas y Consensos recomiendan hacer screening para Lp(a). ¿Cuándo, a quiénes y por qué?(8). Múltiples guías clínicas y consensos de expertos recomiendan hacer screening para Lp(a) con el objetivo de mitigar el riesgo cardiovascular asociado a Lp(a). Se muestra una sinopsis de las recomendaciones claves para la medición de Lp(a) de American Heart Association/American College of Cardiology (AHA/ACC) (6), Canadian Cardiovascular Society (2), and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) clinical guidelines (3); and the ACC, American Association Clinical Endocrinology/American College of Endocrinology (AACE/ACE) (7), EAS (1), and National Lipid Association (NLA) (4-5) consensus statements.
(1) Kronenberg F, Mora S, Stroes ESG et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946.
(2) Pearson GJ, Thanassoulis G, Anderson TJ et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021 Aug;37(8):1129-1150.
(3) Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 2020, 41, 111–188.
(4) Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2019;13:374–92.
(5) Koschinsky M, Bajaj A, Boffa M, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024, 18: e308 - e319.
(6) Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/APhA/
ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 2019;139:e1082–143.
(7) Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary. Endocr Pract 2020;26:1196–224
(8) Gissette Reyes-Soffer, Calvin Yeang b, Erin D Michos, Wess Boatwright, Christie M Ballantyne. High lipoprotein(a): Actionable strategies for risk assessment and mitigation. American Journal of Preventive Cardiology 2024; 18, 100651.